866-997-4948(US-Canada Toll Free)

Actos (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 48 Pages


GlobalData has released its new report, Actos (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Actos (pioglitazone) was launched in 1999 by Takeda Pharmaceuticals; in 2012, generic competitors launched. It is marketed as Actos in the US, Japan, China, Brazil and the UK, as Glustin in other European countries, and as Glizone and Pioz in India.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Actos including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Actos for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Actos performance
  • Obtain sales forecast for Actos from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.1.3 Prognosis 14
3.1.4 Quality of Life 15
3.2 Symptoms 15

4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis and Referrals 17
4.1.2 Treatment Guidelines 18

5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25

6 Actos (pioglitazone) 27
6.1 Overview 27
6.2 Efficacy 28
6.3 Safety 29
6.4 SWOT Analysis 30
6.5 Forecast 31

7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 35
7.3 Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Diagnosed Type 2 Patients 38
7.4.2 Percent Drug-Treated Patients 39
7.4.3 Drugs Included in Each Therapeutic Class 39
7.4.4 Launch and Patent Expiry Dates 40
7.4.5 General Pricing Assumptions 41
7.4.6 Individual Drug Assumptions 42
7.4.7 Generic Erosion 42
7.5 Physicians and Specialists Included in this Study 43
7.6 About the Authors 45
7.6.1 Analyst II - CVMD 45
7.6.2 Therapy Director - CVMD and Infectious Disease 45
7.6.3 Global Head of Healthcare 46
7.7 About GlobalData 47
7.8 Disclaimer 47

List of Table


Table 1: Symptoms of Type 2 Diabetes 16
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 17
Table 3: Treatment Guidelines for Type 2 Diabetes 19
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 22
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 26
Table 6: Product Profile - Actos 28
Table 7: Actos SWOT Analysis, 2012 30
Table 8: Global Sales Forecasts ($m) for Actos, 2012-2022 31
Table 9: Key Launch Dates 40
Table 10: Key Patent Expiries 40
Table 11: Number of High-Prescribing Physicians Surveyed 44

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *